Elsevier tweaks custom pub rules

Publishing company Elsevier is revising its policies and procedures for partnering with pharmaceutical companies to create custom publications in response to recent media attention over a fake journal, called the __Australasian Journal of Bone and Joint Medicine__ (__AJBJM__), created by the company and paid for by Merck. Elsevier provided __The Scientist__ with the names of additional custom publications produced by the company's Australia office from 2000-2005, that an Elsevier spokesperson a

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.


Learn about our editorial policies.

Jun 3, 2009
Publishing company Elsevier is revising its policies and procedures for partnering with pharmaceutical companies to create custom publications in response to recent media attention over a fake journal, called the __Australasian Journal of Bone and Joint Medicine__ (__AJBJM__), created by the company and paid for by Merck. Elsevier provided __The Scientist__ with the names of additional custom publications produced by the company's Australia office from 2000-2005, that an Elsevier spokesperson admitted "should not have been called 'journals'." According to Elsevier, these other publications differed from __AJBJM__ in that they were not sponsored by a single corporation, but were instead paid for by selling "clearly-marked" advertisements purchased by several pharmaceutical companies. Like __AJBJM__, the additional publications did not contain original research. Sponsors had some editorial input, but not as much as Merck had over __AJBJM__, the spokesperson said. "We don't have any indication that any one of our advertisers or sponsors...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?